Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Obstetrics and Gynecology Reports
Published in: Current Obstetrics and Gynecology Reports 1/2012

01-03-2012 | Managing Breast Problems (K Visvanathan, Section Editor)

Breast Cancer Chemoprevention: Current Approachesand Future Directions

Authors: Waseem Khaliq, Kala Visvanathan

Published in: Current Obstetrics and Gynecology Reports | Issue 1/2012

Login to get access

Abstract

Breast cancer is the most commonly diagnosed cancer globally among women and is the leading cause of cancer death. Breast cancer prevention trials have shown up to 50% reduction in breast cancer incidence among women at increased risk for breast cancer with the use of chemopreventive agents. Despite such a large potential reduction in breast cancer risk, the uptake of these agents has been poor as compared with the use of preventive agents for other health outcomes. This review provides an update of the trials evaluating chemoprevention agents for breast cancer and highlights the populations likely to benefit from them. Healthcare providers need to be comfortable with the use of chemopreventive agents for breast cancer, as they are a real option for women at increased risk, particularly those with early precursor lesions. Work is ongoing to identify agents for estrogen receptor–negative cancer and agents with minimal toxicity for more general use.
Literature
1.
2.
Waters EA, Cronin KA, Graubard BI, et al. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev. 2010;19:443–6.PubMedCrossRef
3.
Armstrong K, Quistberg DA, Micco E, et al. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med. 2006;166:2260–5.PubMedCrossRef
4.
Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol. 2005;23:1644–55.PubMedCrossRef
5.
Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852–6.PubMedCrossRef
6.
Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991;115:860–4.PubMed
7.
•• Visvanathan K, Chlebowski RT, Hurley P, et al.: American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009, 27:3235-58. This article provides recommendations for chemoprevention of breast cancer from the American Society of Clinical Oncology, includes a discussion of the chemoprevention trials in detail, and also touches on implementation strategies.
8.
Cusick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296–300.CrossRef
9.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.PubMedCrossRef
10.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–62.PubMedCrossRef
11.
Cuzick J, Forbes J, Edwards R, IBIS investigators, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817–24.PubMedCrossRef
12.
Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272–82.PubMedCrossRef
13.
Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden hospital tamoxifen randomized chemoprevention trial. Lancet. 1998;352:98–101.PubMed
14.
Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99:283–90.PubMedCrossRef
15.
Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007;99:727–37.PubMedCrossRef
16.
Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18:937–47.PubMedCrossRef
17.
Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91:1829–46.PubMedCrossRef
18.
Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology. 2004;12:1230–3.
19.
Noah-Vanhoucke J, Green LE, Dinh TA, et al. Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population. Cancer. 2011;117:3322–31.PubMedCrossRef
20.
Bonanni B, Maisonneuve P, Serrano D, et al.: Safety and efficacy of HRT and low-dose tamoxifen in a phase II trial (HOT): Analysis of mammographic density and endometrial thickness. J Clin Oncol 29: 2011 (suppl; abstr 1527).
21.
Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189–97.PubMedCrossRef
22.
Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751–61.PubMedCrossRef
23.
Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–37.PubMedCrossRef
24.
Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2742–51.PubMedCrossRef
25.
Vogel VG, Costantino JP, Wickerham DL, et al. Update of the national surgical adjuvant breast and bowel project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila). 2010;3:696–706.CrossRef
26.
•• Freedman AN, Yu B, Gail MH, et al.: Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 2011, 29:2327-33. This article provides the most recent risk/benefit analyses for tamoxifen and raloxifene in women age 50 or above and can be used to inform clinical practice.
27.
Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362:686–96.PubMedCrossRef
28.
Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res. 1990;50:4177–89.PubMed
29.
Roy J, Couillard S, Gutman M, et al. A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat. 2003;81:223–9.PubMedCrossRef
30.
Cummings SR, McClung M, Reginster JY, et al. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res. 2011;26:397–404.PubMedCrossRef
31.
Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91.PubMedCrossRef
32.
Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–80.PubMedCrossRef
33.
Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer. ClinicalTrials.gov Identifier: NCT00078832.
34.
Decensi A, Puntoni M, Pruneri G, et al. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila). 2011;4:1181–9.CrossRef
35.
Cauley JA, McTiernan A, Rodabough RJ, et al. Statin use and breast cancer: prospective results from the Women’s Health Initiative. Natl Cancer Inst J. 2006;98:700–7.CrossRef
36.
Kumar AS, Benz CC, Shim V, et al. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev. 2008;17:1028–33.PubMedCrossRef
37.
Garwood ER, Kumar AS, Baehner FL, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010;119:137–44.PubMedCrossRef
38.
Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–6.PubMedCrossRef
39.
Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila). 2010;3:1060–5.CrossRef
40.
Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. Clin Oncol J. 2010;28:3577–81.CrossRef
41.
Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010;28:3582–90.PubMedCrossRef
42.
Lipton A. Emerging role of bisphosphonates in the clinic–antitumor activity and prevention of metastasis to bone. Cancer Treat Rev. 2008;34 Suppl 1:S25–30.PubMedCrossRef
43.
Veronesi U, Mariani L, Decensi A, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol. 2006;17:1065–71.PubMedCrossRef
44.
45.
Sandhu SK, Yap TA, de Bono JS. Poly (ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer. 2010;46:9–20.PubMedCrossRef
46.
Bozovic-Spasojevic I, Azambuja E, McCaskill-Stevens W, et al.: Chemoprevention for breast cancer. Cancer Treat Rev 2011 Aug 17 (Epub ahead of print).
47.
Amir E, Freedman OC, Seruga B, et al. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst. 2010;102:680–91.PubMedCrossRef
48.
Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.PubMedCrossRef
49.
Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007;99:1782–92.PubMedCrossRef
50.
Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer. 1994;73:643–51.PubMedCrossRef
51.
Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111–30.PubMedCrossRef
52.
Bober SL, Hoke LA, Duda RB, et al. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol. 2004;22:4951–7.PubMedCrossRef
53.
Melnikow J, Paterniti D, Azari R, et al. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer. 2005;103:1996–2005.PubMedCrossRef
54.
Taylor R, Taguchi K. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med. 2005;3:242–7.PubMedCrossRef
55.
Fagerlin A, Zikmund-Fisher BJ, Nair V, et al. Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat. 2010;119:613–20.PubMedCrossRef
56.
Ravdin PM. The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention. Cancer Prev Res (Phila). 2010;3:686–8.CrossRef
57.
Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95:526–32.PubMedCrossRef
58.
Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2010;28:3090–5.PubMedCrossRef
Metadata
Title
Breast Cancer Chemoprevention: Current Approachesand Future Directions
Authors
Waseem Khaliq
Kala Visvanathan
Publication date
01-03-2012
Publisher
Current Science Inc.
Published in
Current Obstetrics and Gynecology Reports / Issue 1/2012
Electronic ISSN: 2161-3303
DOI
https://doi.org/10.1007/s13669-011-0005-0

Other articles of this Issue 1/2012

Current Obstetrics and Gynecology Reports 1/2012 Go to the issue

Diagnosis and Management of Adnexal Mass (H Katabuchi, Section Editor)

Clinical Management of Ovarian Endometriotic Cyst (Chocolate Cyst): Diagnosis, Medical Treatment, and Minimally Invasive Surgery

Diagnosis and Management of Adnexal Mass (H Katabuchi, Section Editor)

Evaluation and Management of Women Presenting with a Pelvic Mass

Diagnosis and Management of Adnexal Mass (H Katabuchi, Section Editor)

Ovarian Cancer is an Imported Disease: Fact or Fiction?

Diagnosis and Management of Adnexal Mass (H Katabuchi, Section Editor)

Adnexal Masses in Pediatric and Adolescent Females: A Review of the Literature